Bulk Inquiry
Balicatib
- AAE 581
Axon 2154
CAS:
354813-19-7
Purity:
99%
- Soluble in DMSO
- MF: C23H33N5O2
- MW: 411.54
Description
Balicatib (AAE581) is a selective inhibitor of the osteoclast protease cathepsin K (CTSK). It is used to suppress cathepsin K-mediated collagen degradation and bone matrix resorption.
Cathepsin K is highly expressed in osteoclasts and is a major driver of bone resorption, making it a pharmacological target in osteoporosis and skeletal disease research. Balicatib is relevant for studying protease-mediated bone remodeling.
Key Features
- Selective cathepsin K inhibitor
- Targets osteoclast-associated collagen degradation
- Blocks bone matrix resorption pathways
- Relevant to osteoporosis pharmacology
Applications
- Cathepsin K enzyme assays
- Osteoclast function studies
- Bone resorption model research
- Skeletal disease drug-discovery profiling
More Information
| Parent CAS No. | 354813-19-7 |
|---|---|
| Chemical Name | N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(4-propylpiperazin-1-yl)benzamide |
| SMILES | C(NC1(C(NCC#N)=O)CCCCC1)(=O)C1=CC=C(N2CCN(CCC)CC2)C=C1 |
| MFCD | MFCD19443790 |
| InChi | InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29) |
| InChiKey | LLCRBOWRJOUJAE-UHFFFAOYSA-N |
| CID | 10201696 |
| Short Description | Cathepsin K inhibitor |
References
Other Categories
Get a Quote for
Loading...